Compare Stocks: RCKT, MAZE, TYRA, and ORIC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$29.91 +2.7%	$27.98	$12.91 ▼ $53.65	$1.64B	2.22	656,647 shs	9,992 shs
ORIC Oric Pharmaceuticals	$14.36 +3.2%	$10.96	$7.23 ▼ $14.93	$1.48B	1.02	1.76 million shs	80,095 shs
RCKT Rocket Pharmaceuticals	$3.54 +5.9%	$3.41	$2.53 ▼ $5.45	$382.69M	0.47	2.68 million shs	151,386 shs
TYRA Tyra Biosciences	$26.58 +2.1%	$29.75	$9.96 ▼ $40.65	$1.58B	0.77	897,198 shs	13,105 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	+4.22%	+6.66%	+3.59%	+16.38%	+118.20%
ORIC Oric Pharmaceuticals	+4.04%	+1.38%	+29.73%	+65.52%	+40.61%
RCKT Rocket Pharmaceuticals	-1.76%	-4.57%	-2.91%	+12.46%	+10.23%
TYRA Tyra Biosciences	-0.69%	+3.42%	-18.95%	-22.04%	+140.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$29.91 +2.7%	$27.98	$12.91 ▼ $53.65	$1.64B	2.22	656,647 shs	9,992 shs
ORIC Oric Pharmaceuticals	$14.36 +3.2%	$10.96	$7.23 ▼ $14.93	$1.48B	1.02	1.76 million shs	80,095 shs
RCKT Rocket Pharmaceuticals	$3.54 +5.9%	$3.41	$2.53 ▼ $5.45	$382.69M	0.47	2.68 million shs	151,386 shs
TYRA Tyra Biosciences	$26.58 +2.1%	$29.75	$9.96 ▼ $40.65	$1.58B	0.77	897,198 shs	13,105 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	+4.22%	+6.66%	+3.59%	+16.38%	+118.20%
ORIC Oric Pharmaceuticals	+4.04%	+1.38%	+29.73%	+65.52%	+40.61%
RCKT Rocket Pharmaceuticals	-1.76%	-4.57%	-2.91%	+12.46%	+10.23%
TYRA Tyra Biosciences	-0.69%	+3.42%	-18.95%	-22.04%	+140.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MAZE Maze Therapeutics	3.00	Buy	$66.00	120.65% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$19.45	35.44% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	142.34% Upside
TYRA Tyra Biosciences	2.87	Moderate Buy	$46.90	76.42% Upside

Current Analyst Ratings Breakdown

Latest RCKT, MAZE, TYRA, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/5/2026	TYRA Tyra Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TYRA Tyra Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	MAZE Maze Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/17/2026	TYRA Tyra Biosciences	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MAZE Maze Therapeutics	$167.50M	9.92	N/A	N/A	$7.38 per share	4.05
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)

Latest RCKT, MAZE, TYRA, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MAZE Maze Therapeutics	0.09	18.31	18.31
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24
TYRA Tyra Biosciences	N/A	14.90	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MAZE Maze Therapeutics	N/A
ORIC Oric Pharmaceuticals	95.05%
RCKT Rocket Pharmaceuticals	98.39%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
MAZE Maze Therapeutics	5.30%
ORIC Oric Pharmaceuticals	5.70%
RCKT Rocket Pharmaceuticals	21.30%
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable
TYRA Tyra Biosciences	20	59.68 million	52.22 million	Optionable

RCKT, MAZE, TYRA, and ORIC Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline?

August 17 at 9:50 PM | kalkinemedia.comK

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2% - Time to Buy?

August 17 at 1:39 PM | marketbeat.com

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

August 15, 2026 | marketbeat.com

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

August 10, 2026 | seekingalpha.com

Q3 EPS Estimate for Tyra Biosciences Reduced by Analyst

August 9, 2026 | americanbankingnews.com

HC Wainwright Brokers Lower Earnings Estimates for TYRA

August 7, 2026 | marketbeat.com

Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 6, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings

August 5, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

August 4, 2026 | marketbeat.com

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

August 4, 2026 | prnewswire.com

Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA

August 3, 2026 | marketbeat.com

Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP

August 2, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA

August 1, 2026 | marketbeat.com

Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP

July 28, 2026 | marketbeat.com

Commodore Capital LP Lowers Stake in Tyra Biosciences, Inc. $TYRA

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Makes New $9.86 Million Investment in Tyra Biosciences, Inc. $TYRA

July 25, 2026 | marketbeat.com

Jennison Associates LLC Buys Shares of 632,432 Tyra Biosciences, Inc. $TYRA

July 21, 2026 | marketbeat.com

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

June 30, 2026 | finance.yahoo.com

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

June 30, 2026 | finance.yahoo.com

Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight

June 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, MAZE, TYRA, and ORIC Company Descriptions

Maze Therapeutics NASDAQ:MAZE

$29.91 +0.78 (+2.68%)

As of 10:05 AM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Oric Pharmaceuticals NASDAQ:ORIC

$14.36 +0.44 (+3.19%)

As of 10:05 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.54 +0.20 (+5.90%)

As of 10:05 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Tyra Biosciences NASDAQ:TYRA

$26.58 +0.54 (+2.09%)

As of 10:05 AM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, MAZE, TYRA, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, MAZE, TYRA, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, MAZE, TYRA, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, MAZE, TYRA, and ORIC Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Oric Pharmaceuticals NASDAQ:ORIC

Rocket Pharmaceuticals NASDAQ:RCKT

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, MAZE, TYRA, and ORIC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, MAZE, TYRA, and ORIC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, MAZE, TYRA, and ORIC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, MAZE, TYRA, and ORIC Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Oric Pharmaceuticals NASDAQ:ORIC

Rocket Pharmaceuticals NASDAQ:RCKT

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools